Glucagon-like Peptide-2 and Mouse Intestinal Adaptation to a High-fat Diet
Overview
Affiliations
Endogenous glucagon-like peptide-2 (GLP2) is a key mediator of refeeding-induced and resection-induced intestinal adaptive growth. This study investigated the potential role of GLP2 in mediating the mucosal responses to a chronic high-fat diet (HFD). In this view, the murine small intestine adaptive response to a HFD was analyzed and a possible involvement of endogenous GLP2 was verified using GLP2 (3-33) as GLP2 receptor (GLP2R) antagonist. In comparison with animals fed a standard diet, mice fed a HFD for 14 weeks exhibited an increase in crypt-villus mean height (duodenum, 27.5±3.0%; jejunum, 36.5±2.9%; P<0.01), in the cell number per villus (duodenum, 28.4±2.2%; jejunum, 32.0±2.9%; P<0.01), and in Ki67-positive cell number per crypt. No change in the percent of caspase-3-positive cell in the villus-crypt was observed. The chronic exposure to a HFD also caused a significant increase in GLP2 plasma levels and in GLP2R intestinal expression. Daily administration of GLP2 (3-33) (30-60 ng) for 4 weeks did not modify the crypt-villus height in control mice. In HFD-fed mice, chronic treatment with GLP2 (3-33) reduced the increase in crypt-villus height and in the cell number per villus through reduction of cell proliferation and increase in apoptosis. This study provides the first experimental evidence for a role of endogenous GLP2 in the intestinal adaptation to HFD in obese mice and for a dysregulation of the GLP2/GLP2R system after a prolonged HFD.
Sellami E, Evangelista-Silva P, Jordao Teixeira C, Diop K, Mitchell P, Forato Anhe F Mol Metab. 2025; 93:102101.
PMID: 39855562 PMC: 11830333. DOI: 10.1016/j.molmet.2025.102101.
Elhessy H, Berika M, Salem Y, El-Desoky M, Eldesoqui M, Mostafa N Heliyon. 2024; 10(7):e28436.
PMID: 38560252 PMC: 10979098. DOI: 10.1016/j.heliyon.2024.e28436.
Adachi H, Ishiyama S, Mochizuki K Biochem Biophys Rep. 2023; 34:101475.
PMID: 37197734 PMC: 10183655. DOI: 10.1016/j.bbrep.2023.101475.
Velazquez E, Le Baut Ayuso Y, Blazquez E, Ruiz-Albusac J J Alzheimers Dis Rep. 2023; 6(1):723-732.
PMID: 36606205 PMC: 9741749. DOI: 10.3233/ADR-220043.
Gabe M, Gasbjerg L, Gadgaard S, Lindquist P, Holst J, Rosenkilde M Br J Pharmacol. 2022; 179(18):4473-4485.
PMID: 35523760 PMC: 9541843. DOI: 10.1111/bph.15866.